Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy

Br J Haematol. 2020 May;189(4):e126-e130. doi: 10.1111/bjh.16550. Epub 2020 Mar 2.

Authors

Affiliations

¹ Icahn School of Medicine at Mount Sanai, New York, NY, USA.
² Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
³ University of Chicago Medical Center, Chicago, IL, USA.
⁴ Karyopharm Therapeutics, Newton, MA, USA.

PMID: 32124443
DOI: 10.1111/bjh.16550

No abstract available

Keywords: bortezomib; carfilomib; chimeric antigen receptor T cell refractory; multiple myeloma; selinexor.

Publication types

Letter

MeSH terms

Adult
Aged
Cell- and Tissue-Based Therapy / methods*
Female
Humans
Hydrazines / pharmacology
Hydrazines / therapeutic use*
Male
Middle Aged
Multiple Myeloma / drug therapy*
Receptors, Chimeric Antigen / therapeutic use*
Triazoles / pharmacology
Triazoles / therapeutic use*

Substances

Hydrazines
Receptors, Chimeric Antigen
Triazoles
selinexor